Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias

Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies.

This second edition of Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias includes:
- the new IMWG SLiM CRAB criteria
- the latest advances in diagnostic tests and imaging
- cytogenetics and genetic profiling
- induction therapy prior to SCT
- new lenalidomide- and bortezomib-based regimens
- second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments.

This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice.